Projects Funded by the Interleukin-1 Foundation
A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF ANAKINRA IN PATIENTS WITH HIDRADENITIS SUPPURATIVA.
Support of the Auto-Inflammatory Workshop in Amsterdam in September, 2010.
TESTING SPECIFIC INHIBITION OF SPI-1/PU.1 FOR IL‑1b PRECURSOR BLOCKADE IN HUMAN MONOCYTES.
ANAKINRA FOR THE TREATMENT OF WOLFRAM’S SYNDROME.
Anakinra for prevention of cerebral edema during treatment of diabetic ketoacidosis.
Mechanisms of IL-37-mediated immunosuppression in skin inflammation.
Aralast NP for treating patients with Grade 4 GVHD and steroid resistance.
Molecular mechanisms of histone deacetylase inhibitor (HDACi)-mediated pancreatic beta-cell protection.
A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF ANAKINRA IN PATIENTS WITH HIDRADENITIS SUPPURATIVA.
Support of the Auto-Inflammatory Workshop in Amsterdam in September, 2010.
TESTING SPECIFIC INHIBITION OF SPI-1/PU.1 FOR IL‑1b PRECURSOR BLOCKADE IN HUMAN MONOCYTES.
ANAKINRA FOR THE TREATMENT OF WOLFRAM’S SYNDROME.
Anakinra for prevention of cerebral edema during treatment of diabetic ketoacidosis.
Mechanisms of IL-37-mediated immunosuppression in skin inflammation.
Aralast NP for treating patients with Grade 4 GVHD and steroid resistance.
Molecular mechanisms of histone deacetylase inhibitor (HDACi)-mediated pancreatic beta-cell protection.